NCT05592015View on ClinicalTrials.gov

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 3, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
T-Cell Large Granular Lymphocyte Leukemia
Interventions
DRUG

Ruxolitinib

Given PO

Trial Locations (3)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Jonathan Brammer

OTHER